With the evolution of precision medicine in oncology, liquid biopsy has played an important role in leading precision treatment. Guardant Health, a leading precision oncology company has license Adicon to offer Guardant Health’s comprehensive genomic profiling test to biopharmaceutical companies conducting clinical trials in China. This encourages more multi-national biopharmaceutical companies to bring their global clinical trials to China and support drug development of China-based biopharmaceutical companies to go global.

You are sincerely invited to attend the Guardant Health & Adicon launch meeting. The meeting will discuss the application of liquid biopsy in the clinical research of new tumor drugs with experts in the industry, and jointly help the research and development of anti-tumor drugs in China.